Amgen touts two cancer study wins amid second-quarter earnings update

Two cancer drugs succeeded in mid- or late-stage clinical studies, Amgen said Thursday in its second-quarter earnings announcement.

Peter Griffith

“Momentum is building in the pipeline,” Amgen CFO Peter Griffith told Endpoints News, adding the biotech plans to discuss both datasets with regulators, calling a study…
Click here to view original post